DNP, Rush University
BSN, University of Cincinnati
BA, Indiana University
Rare inherited diseases (Niemann Pick Type C, Fragile X Syndrome), associated developmental and degenerative disorders, supportive care needs of parents and caregivers of individuals with rare disease, ADHD, anxiety and mood disorders in children, adolescents and young adults.
Friedmann, K. (2020). Supportive care needs in rare disease: evaluation of an expanded access program for Niemann Pick Disease Type C. Presented at the Michael, Marcia & Christa Parseghian Scientific Conference, Tucson, AZ.
Berry-Kravis, E., Chin, J., Jaeger, R., Friedmann, K., Hoffmann, A., Wainer, A., Leonczyk, C., Soorya, L., Farhat, N., Porter, F. (2019). Impact of intrathecal 2-hydroxylpropyl-beta-cyclodextrin (HP-B-CD, VTS-270) on cognitive decline in NPC1. Michael, Marcia & Christa Parseghian Scientific Conference, Tucson, AZ.
Jaeger R., Friedmann K., Leonczyk C., Hoffmann A., Wainer A., … Porter, F. (2019). Effects of Hydroxypropyl-beta-cyclodextrin HB-B-CD, VTS-270 in children with NPC1 age 5 and under: Comparison to natural history. Michael, Marcia & Christa Parseghian Scientific Conference, Tucson, AZ.
Friedmann, K. (2018). Updates to the implementation of a national, multi-site, expanded access program for the treatment of neurological disease in Niemann Pick disease type C1 with intrathecal VTS-270. Michael, Marcia and Christa Parseghian Scientific Conference for Niemann-Pick Type C Research, Tucson, AZ.
Berry-Kravis, E., Seinfeld, S., Chin, J., Friedmann, K., O’Hara, K. (2018). Protriptyline and severe cataplexy in Niemann-Pick type C1. Michael, Marcia & Christa Parseghian Scientific Conference, Tucson, AZ.
Berry-Kravis, E., Chin, J., Friedmann, K., Wainer, A., Leonczyk, C., Gonring, K., Hoffmann, A. (2018). Impact of treatment with intrathecal 2-hydroxy-beta-cyclodextrin (HP-B-CD, VTS-270) on cognitive decline in NPC1. Michael, Marcia & Christa Parseghian Scientific Conference, Tucson, AZ.
Berry-Kravis, E., Chin, J., Friedmann, K., Hernandez, M., Nadelman, A., … O’Keefe J. (2018). Treatment of very young children with intrathecal 2-hydroxy-beta-cyclodextrin (VTS-270): Experience with 6 NPC1 patients. Michael, Marcia & Christa Parseghian Scientific Conference, Tucson, AZ.
Friedmann, K. (2017). Implementation of a national, multisite, expanded access program for Niemann Pick disease type C1. Oral presentation, National Niemann Pick Disease Foundation Annual Family Conference, Chicago, IL.
Berry-Kravis, E., O’Keefe, J., Hoffmann, A., LaGorio, L., Friedmann, K., … Ardestani, M. (2017). Arrest of progression of Niemann-Pick type C1 (NPC) with intrathecal 2-hydroxypropyl-ß-cyclodextrin (VTS-270) in multiple neurological domains for 3 years. Michael, Marcia & Christa Parseghian Scientific Conference, Tucson, AZ.
Friedmann, K., Hernandez, M., Chin, J., Mishos, C., … Berry-Kravis, E. (2016). Implementation of a national, multi-site, expanded access program for the treatment of neurological disease in Niemann Pick disease type C1, with intrathecal VTS-270. Michael, Marcia and Christa Parseghian Scientific Conference for Niemann-Pick Type C Research, Tucson, AZ.
Berry-Kravis, E., O’Keefe, J., Hoffmann, A., Winston, A., Stoner, R., … Friedmann, K. (2016). Performance on objective clinical efficacy outcome measures during long-term cyclodextrin (VTS-270) treatment in NPC. Michael, Marcia & Christa Parseghian Scientific Conference, Tucson, AZ.
Berry-Kravis, E., O’Keefe, J., Hoffmann, A., Winston, A., Stoner, R., … Friedmann, K. (2016). Performance on objective clinical efficacy outcome measures during long-term cyclodextrin (VTS-270) treatment in NPC. National Niemann-Pick Disease Foundation Family Conference, Boston, MA.